New FDA guidance documents

被引：0

作者：

Bradshaw, Sheldon T. ^{[1
]}

机构：

[1] US FDA, Rockville, MD 20857 USA

来源：

关键词：

D O I：

暂无

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

引用

页码：429 / 431

页数：3

共 50 条

[1] New FDA xenotransplantation documents: a proposed rule and a draft guidance
Bloom, ET
[J]. XENOTRANSPLANTATION, 2001, 8 (03) : 153 - 154
[2] FDA stability draft guidance documents
不详
[J]. LARGE ANIMAL PRACTICE, 1998, 19 (06): : 12 - 12
[3] New FDA Draft Guidance on Immunogenicity
Ashwin Parenky
Heather Myler
Lakshmi Amaravadi
Karoline Bechtold-Peters
Amy Rosenberg
Susan Kirshner
Valerie Quarmby
[J]. The AAPS Journal, 2014, 16 : 499 - 503
[4] FDA Guidance and New Drug Approvals
Walker, Scot
[J]. HOSPITAL PHARMACY, 2018, 53 (06) : 360 - 362
[5] New FDA Draft Guidance on Immunogenicity
Parenky, Ashwin
Myler, Heather
Amaravadi, Lakshmi
Bechtold-Peters, Karoline
Rosenberg, Amy
Kirshner, Susan
Quarmby, Valerie
[J]. AAPS JOURNAL, 2014, 16 (03): : 499 - 503
[6] New guidance documents for reporting of marketed products
[J]. Reactions Weekly, 2018, 1705 (1) : 2 - 2
[7] New guidance documents on accident hazard regulations
不详
[J]. JOURNAL OF THE SOCIETY OF DYERS AND COLOURISTS, 1999, 115 (11): : 331 - 331
[8] New Guidance Documents for Reporting of Marketed Products
不详
[J]. PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 295 - 295
[9] Publication of new issues of ENIQ guidance documents
不详
[J]. INSIGHT, 2019, 61 (09) : 497 - 498
[10] Issues in applying recent CPMP 'Points to Consider' and FDA guidance documents with biostatistical implications
Phillips, A
Ebbutt, A
France, L
Morgan, D
Ireson, M
Struthers, L
Heimann, G
[J]. PHARMACEUTICAL STATISTICS, 2003, 2 (04) : 241 - 251